CCM
BIB icon

Chilton Capital Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Chilton Capital Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39
Closed -$1.79K – 572
2025
Q2 		$1.79K Hold
39
– – ﹤0.01% 504
2025
Q1 		$1.88K Buy
+39
New +$2.09K ﹤0.01% 505

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Chilton Capital Management's BIB Position: Q3 2025 in Review

Chilton Capital Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2025, closing a stake of 39 shares — an estimated $1.79K sold.

Chilton Capital Management first reported a position in BIB in Q1 2025 and held it in 2 quarters. The position peaked at $1.88K in Q1 2025. 19 funds tracked by Wall St. Rank hold BIB as of Q3 2025.

  • Chilton Capital Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Chilton Capital Management sold 39 ProShares Ultra NASDAQ Biotechnology shares in Q3 2025, an estimated $1.79K.
  • Chilton Capital Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2025 and held it in 2 quarters.
  • Chilton Capital Management's ProShares Ultra NASDAQ Biotechnology position peaked at $1.88K in Q1 2025.
  • 19 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2025.

Based on Chilton Capital Management's 13F filing for Q3 2025, filed 31 Oct 2025.